T he enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to inhibit the enzyme has been explored. Several DPP-4 inhibitors are in clinical development; these are orally active and increase levels of active GLP-1, which in turn increases insulin secretion and reduces glucagon secretion and thereby lowers glucose levels. Most experience exists for sitagliptin (Merck) and vildagliptin (Novartis), which both have a long duration of action, allowing oncedaily administration. In drug-naïve subjects with type 2 diabetes, both sitagliptin and vildagliptin reduce A1C levels by ϳ1% as monotherapy, as demonstrated in studies up to 52 weeks. Also in combination with metformin and thiazolidinediones, sitagliptin and vildagliptin improve glycemic control with reduction of A1C of ϳ1%. Both sitagliptin and vildagliptin are safe and tolerable with low risk of hypoglycemia. They are both body weight neutral. The studies presented thus far therefore suggest that DPP-4 inhibition is an efficient treatment of type 2 diabetes, both as monotherapy and combination therapy. Because of its efficiency, safety, and tolerability in association with the oral mode of administration, it is expected that DPP-4 inhibition will be a first-line treatment of the early stage of type 2 diabetes, particularly in combination with metformin or thiazolidinediones.
GLP-1 AS AN ANTIDIABETIC HORMONE -
GLP-1 is one of the important incretin hormones; it is released after meal ingestion and stimulates insulin secretion (1) . GLP-1 also exhibits strong antidiabetic actions, as initially demonstrated already in the early 1990s (2) (3) (4) . Thus, infusion of GLP-1 lowers circulating glucose through a combination of stimulation of insulin secretion and inhibition of glucagon secretion. A 6-week study with continuous subcutaneous infusion of GLP-1 showed reduction in fasting and prandial glycemia along with reduction in A1C and improvement both in insulin secretion and insulin action and reduction in body weight, which illustrates the potency of GLP-1-based therapy (5) .
DPP-4 INACTIVATION OF GLP-1 -It was early understood that
GLP-1 is unattractive as chronic therapy of diabetes because the hormone is rapidly inactivated by the action of the enzyme DPP-4 (6). This enzyme is widely expressed in several organs and circulates in a soluble form (7) . It acts by cleavage of the two NH 2 -terminal amino acids of bioactive peptides, provided that the second amino acid is alanine or proline. Since the second NH 2 -terminal amino acid in GLP-1 is alanine, GLP-1 is cleaved to a truncated form [sometimes called GLP-1 (9-36)amide] (6). This truncated form of GLP-1 is largely inactive; therefore, the cleavage of GLP-1 by DPP-4 is an inactivation process. The cleavage is rapid, which is the reason why native GLP-1 has a short half-life (Ͻ2 min). Therefore, it is necessary to use multiple daily injections of continuous subcutaneous infusion of GLP-1 for maintenance of glycemic control when using the native GLP-1.
TWO STRATEGIES FOR GLP-1-BASED THERAPY -To harness the antidiabetic action of GLP-1 and at the same time overcome the problem of the rapid inactivation of the native hormone, two strategies have been explored. Both these strategies have been shown to be successful. One approach is to use GLP-1 receptor agonists (GLP-1 mimetics), which are not degraded by DPP-4. A representative of this approach is exenatide (Byetta; Lilly) (8) , which is now approved for use in the treatment of diabetes both in the U.S. and Europe. Liraglutide (Novo Nordisk) is another example of this strategy. The other approach for GLP-1-based therapy is to inhibit the enzyme activity of DPP-4 (1,9 -13).
DPP-4 inhibition as a strategy to treat diabetes
The rationale for the strategy of inhibiting DPP-4 in the treatment of type 2 diabetes is to prevent the inactivation of GLP-1 and therefore to enhance and prolong the action of the endogenously released incretin hormone. This strategy was first summarized by Holst and Deacon (14) , who showed that DPP-4 inhibition increases circulating levels of GLP-1 in experimental animals and that the insulinotropic action of exogenously administered GLP-1 is augmented by DPP-4 inhibition. Later studies demonstrated that the prevention of inactivation of GLP-1 by DPP-4 inhibition markedly increases the active GLP-1 in the circulation. For example, as shown in dogs, the active GLP-1 under fasting conditions accounts for only ϳ10% of total GLP-1, whereas after DPP-4 inhibition 99% of GLP-1 is in the active form (15) . The increase in concentrations of active GLP-1 following administration of DPP-4 inhibitors has subsequently been confirmed in clinical studies (Fig. 1) . It has also been demonstrated that DPP-4 inhibition increases not only prandial but also fasting levels of active GLP-1 (16) . In fact, DPP-4 inhibition results in an overall increase in GLP-1 levels with preserved circadian rhythm throughout the day (Fig.  2) . Since DPP-4 is also the inactivation enzyme for the other incretin hormone, glucose-dependent insulinotropic polypeptide (GIP) (5), the concentrations of active GIP are also increased throughout the 24-h period after DPP-4 inhibition (16). This is, however, probably of less importance for the antidiabetic action of DPP-4 inhibition, since GIP seems to have lost much of its insulinotropic action in diabetes and, furthermore, since GIP stimulates rather than inhibits glucagon secretion (17) .
Early studies on DPP-4 inhibition
The strategy to inhibit DPP-4 as a treatment of diabetes was initially verified in animal studies, which demonstrate that genetic deletion of DPP-4 (18) or pharmacological inhibition of DPP-4 improves glucose tolerance and insulin secretion in a variety of experimental models (12,19 -21) . The final proof-of-concept study in humans was published in 2002 (22) . Patients with drug-naïve type 2 diabetes (mean age 65 years, mean BMI 27 kg/m 2 , mean A1C 7.4%, and mean fasting glucose 9.0 mmol/l) were treated with the DPP-4 inhibitor NVP-DPP728 (Novartis).
It was found that following a 4-week treatment period, fasting, prandial, and mean glucose levels were reduced by Ͼ1 mmol/l, and even though the study was only 4 weeks in duration, A1C was lowered by 0.5%. The treatment was also highly tolerable and safe, suggesting the feasibility of this approach for the treatment of type 2 diabetes.
Vildagliptin and sitagliptin
Following these initial animal studies and the successful proof-of-concept study in humans, several DPP-4 inhibitors have been developed, which are in different stages in clinical development (Table 1) . Vildagliptin (LAF237, Galvus; Novartis) and sitagliptin (MK-0431, Januvia; Merck) have been explored in detail (23) (24) (25) . They are orally active and rapidly absorbed, and both efficiently inhibit plasma DPP-4 activity-plasma DPP-4 activity is inhibited by almost 100% already at 15-30 min after oral administration, and Ͼ80% inhibition lasts for Ͼ16 h (26). They are therefore both possible to administer once daily; sitagliptin has been approved by the Food and Drug Administration (FDA) (October 2006), whereas vildagliptin has been applied for approval. Both compounds are planned to be used in a dose of 100 mg once daily. Whereas hepatic insufficiency does not seem to alter pharmacokinetics of the compounds, renal insufficiency increases circulating sitagliptin (28) . Therefore, in patients with moderate (creatinine clearance Ͻ50 ml/min) or severe (creatinine clearance Ͻ30 ml/min) renal insufficiency, the dose of sitagliptin should be reduced to 50 and 25 mg, respectively, and the FDA recommends that renal func- Vildagliptin and sitagliptin as monotherapy Vildagliptin. In the first clinical study with vildagliptin, 100 mg once daily was administered to 18 drug-naïve patients with type 2 diabetes for 4 weeks and the effects compared with a placeboadministered group (n ϭ 19). The patients had a mean baseline glucose of 8.8 mmol/l and a mean baseline A1C of 7.2% (26) . It was found that vildagliptin reduced fasting glucose by ϳ0.7-0.9 mmol/l and prandial glucose by 1.5 mmol/l, and A1C also was significantly reduced (26) . A subsequent study in patients with type 2 diabetes with a mean baseline A1C of 7.7% showed that after 12-week treatment with vildagliptin at 50 or 100 mg once daily, A1C had been reduced by 0.46 and 0.40%, respectively, compared with the nonsignificant 0.13% reduction of A1C in the placebo group (29) . In a third study, vildagliptin was given as monotherapy at 25 mg twice daily for 12 weeks (30). It was demonstrated that both fasting and prandial glucose were reduced and that A1C was reduced by 0.6% from a mean baseline of 8.0%. These placebo-controlled studies thus showed that vildagliptin efficiently improved glycemic control. Moreover, vildagliptin was safe and tolerable with adverse events of the same degree as in the placebo groups. Furthermore, the number of hypoglycemic events was very low, which is expected from the glucose dependency of the action. Another study showed that during a 24-week period in 354 drug-naïve patients with type 2 diabetes (baseline A1C 8.4%), A1C was reduced by 0.5% by vildagliptin at 50 mg once daily, by 0.7% by vildagliptin at 50 mg twice daily, and by 0.9% by vildagliptin at 100 mg once daily (31) . Vildagliptin was well tolerated in all groups. This shows that 100 mg vildagliptin provides similar clinical benefit when given as single dose or divided.
In two studies, vildagliptin as monotherapy has been compared with other active treatment modalities. A 24-week study compared the effect of vildagliptin (50 mg twice daily; n ϭ 519) with that of rosiglitazone (8 mg once daily; n ϭ 267) in subjects with type 2 diabetes (32). The subjects were drug-naïve patients with a mean baseline A1C level of 8.7% and a mean diabetes duration of 2.4 years. Following the 24-week treatment, vildagliptin reduced A1C by 1.1%. The reduction was seen during the first 5-10 weeks, and then a sustained effect of vildagliptin was evident. The reduction in A1C was not significantly different from the reduction with rosiglitazone, which was 1.3%. Vildagliptin was safe and tolerable and showed a lower degree of adverse events than rosiglitazone. One mild hypoglycemic event was evident in each group, and whereas patients given rosiglitazone experienced an increase in body weight by 1.6 kg, those given vildagliptin had no significant change in body weight. The incidence of edema was greater with rosiglitazone (4.1%) than vildagliptin (2.1%). Vildagliptin as monotherapy at 50 mg twice daily (n ϭ 526) is also being compared with treatment with metformin at 1 g twice daily (n ϭ 254) in subjects with type 2 diabetes (33). The subjects were, again, drug-naïve patients with a mean diabetes duration of 2.4 years, and they had a mean baseline A1C of 8.7%. It was found that vildagliptin reduced A1C by 1.0%, whereas metformin reduced A1C by 1.4%; hence, although noninferiority versus metformin was not reached, vildagliptin also showed a clinically meaningful reduction of A1C in this study. Again, vildagliptin was safe and tolerable; three patients reported mild hypoglycemic events in the vildagliptin plus metformintreated group versus one patient in the metformin-treated group. Sitagliptin. The first study using sitagliptin as monotherapy evaluated the compound in 743 drug-naïve patients with type 2 diabetes using different doses for a treatment duration of 12 weeks (34). The patients had a mean baseline A1C of 7.7% and were inadequately treated with diet and exercise. Sitagliptin was given at the doses of 5, 12.5, 25, or 50 mg twice daily. It was found that after 12 weeks, all groups given sitagliptin had displayed a significant reduction in A1C in relation to placebo, with the largest reduction versus placebo (0.77%) at the dose of 50 mg twice daily. In one arm of the study, glipizide was given at 5 mg daily with elective titration to 20 mg daily. In this group, A1C was reduced by 1.0%. Hypoglycemic events were observed in 17% of patients given glipizide versus Ͻ1% in the sitagliptin groups. Whereas body weight increased in subjects given glipizide (by 1.1 kg), no significant change in body weight was observed in subjects given sitagliptin. Another study examined the influence of sitagliptin as monotherapy over 12 weeks versus placebo; a total of 552 patients were included. They were all drug-naïve patients and had a mean baseline A1C level of 7.7%. Sitagliptin was given at 25, 50, or 100 mg once daily or 50 mg twice daily, and it was found that the largest reduction in A1C (by 0.6%) was observed by the dose of 100 mg daily (35) . This was accompanied by a reduction in fasting glucose by 0.9 mmol/l. Furthermore, an 18-week study comprising 521 patients using sitagliptin at 100 or 200 mg once daily as monotherapy versus placebo in patients with an initial A1C level of 8.1% showed a reduction in A1C by 0.60 and 0.48%, respectively (36; Fig.  3 ). Finally, a 24-week study using sitagliptin at 100 or 200 mg daily in drugnaïve patients with type 2 diabetes with a mean baseline A1C of 8.0% showed a reduction by 0.74 and 0.94%, respectively (37). In conclusion, studies using vildagliptin or sitagliptin as monotherapy in patients with type 2 diabetes show good efficiency to improve the glycemic control with a reduction in A1C of ϳ0.8 -1.1% over 12-52 weeks of treatment. As in most studies in type 2 diabetes, subjects with the highest baseline A1C levels have the largest reduction in A1C; therefore, when directly comparing the degree of reduction, this must be taken into account. Finally, in monotherapy there is no indication of differences in efficacy between younger and older subjects and no relation to degree of obesity, although results in these subsets of patients are not always clearly reported.
Vildagliptin and sitagliptin in combination therapy
Vildagliptin. Studies have reported the experience of treatment with a DPP-4 inhibitor in combination with metformin, a thiazolidinedione, or insulin. The first study with vildagliptin in combination therapy was a 52-week trial in which the compound was added at the dose of 50 mg daily to ongoing treatment with metformin (39) . The patients had a mean age of 57 years, a mean diabetes duration of 5.5 years, a mean of 2.3 years of ongoing treatment with metformin (1.5-3.0 g daily), and a mean baseline A1C of 7.8%. The study was designed as an initial core study for 12 weeks (n ϭ 107), which was followed by a 40-week extension period in a subset of patients (n ϭ 71). The results showed that during the initial 12-week study period, vildagliptin in combination with metformin reduced A1C levels by 0.7% compared with metformin alone. Furthermore, during the following 40 weeks, A1C increased by 0.066% per month in patients given metformin alone, whereas in subjects given vildagliptin in combination with metformin the rate of increase in A1C was only 0.013% per month (Fig. 4) . This suggests the progressive deterioration in glycemic control seen in patients treated with metformin was prevented by addition of vildagliptin. A larger study comprising altogether 416 patients examined the addition of vildagliptin at 50 mg once or twice daily to ongoing treatment with metformin (40) . The patients had a mean diabetes duration of 6.2 years and a mean baseline A1C of 8.4%. The results show, again, a reduction in A1C in the groups given vildagliptin in combination with metformin when compared with the control group given metformin alone; the reduction in A1C was 0.7% in the group given 50 mg once daily and 1.1% in the group given vildagliptin at 50 mg twice daily. Vildagliptin has also been examined when used in combination with pioglitazone in a 6-month study involving 592 patients who were assigned to treatment with vildagliptin alone at 100 mg daily, with vildagliptin at 50 or 100 mg in combination with pioglitazone at 15 or 30 mg, respectively, or with pioglitazone alone at 30 mg daily (41) . Baseline A1C was 8.7%, and a large reduction in A1C (1.9%) was observed in the group treated with vildagliptin at 100 mg in combination with pioglitazone at 30 mg daily. Finally, vildagliptin has also been added to insulin in subjects with more advanced type 2 diabetes in a 24-week study (42) . In this study, mean duration of diabetes was 14.6 years and patients had been treated with insulin for a mean duration of 6.3 years. The mean daily insulin dose was 82 units, and mean baseline A1C was 8.9%; this was reduced by 0.5% in the group given vildagliptin with insulin versus 0.2% in the group given insulin alone. Hypoglycemic events were less common and less severe in the patients given vildagliptin in combination with insulin (33 patients, 113 events, 0 severe events) versus in those given insulin alone (45 patients, 185 events, 6 severe events). Hence, in combination with insulin, vildagliptin reduced A1C more markedly than insulin alone, and this was associated with a reduced risk of hypoglycemia. Also, sitagliptin has been evaluated in combination with metformin. In a 6-month study comprising 701 patients, sitagliptin (100 mg daily) was added to ongoing metformin (Ͼ1.5 g daily) in subjects with a mean baseline A1C of 8.0%. A1C was reduced by 0.65% by sitagliptin compared with placebo (43) . In another large study comprising a total of 1,172 patients, the effect of sitagliptin (100 mg daily) in combination with metformin was compared with glipizide (up to 20 mg daily) as add-on to metformin during a study period of 52 weeks. The included subjects had a mean baseline A1C of 7.5%, and it was reported that in both groups A1C was reduced by 0.67% (44) . The study reported two important differences between the groups-the number of hypoglycemic events was strikingly higher in the group given glipizide (32%) than in the group given sitagliptin (4.9%), and body weight increased in subjects given glipizide (by 1.5 kg) but decreased in subjects given sitagliptin (by 1.5 kg). Sitagliptin (100 mg daily, n ϭ 175) has also been examined versus placebo (n ϭ 178) as add-on to pioglitazone at 30 or 45 mg daily for 6 months in patients with a diabetes duration of 6.1 years and a mean baseline A1C of 8.0% (45) . Compared with placebo, A1C was reduced by 0.7% by sitagliptin in combination with pioglitazone. Sitagliptin was well tolerated, and the proinsulin-to-insulin ratio was reduced in the group treated with sitagliptin. The studies presented thus far with vildagliptin and sitagliptin in combination therapy therefore show good efficacy in combination with both metformin and thiazolidinediones in studies of at least 6 months' duration. Mean A1C levels are reduced by ϳ0.6 -1%, with the highest reduction in subjects with highest baseline A1C levels.
Safety and tolerability of DPP-4 inhibitors
Both vildagliptin and sitagliptin are tolerable and safe with an adverse events profile similar to that of placebo-administered patients in clinical studies. Also, the reported numbers of hypoglycemia are very low during DPP-4 inhibition, which is expected from the glucose dependency on the effects of GLP-1. Reports on effects of DPP-4 inhibition on blood pressure are few, and when reported, no 24-h measurements have been undertaken. Most studies report no effect on blood pressure. However, in one 24-week study with vildagliptin in combination with metformin, a slight reduction in blood pressure was seen in the group given vildagliptin (systolic blood pressure reduction of 2 vs. Ϫ0.3 mmHg in the placeboadministered group; the difference being significant) (40) . This deserves further study. Furthermore, frequency of electrocardiogram abnormalities during treatment with DPP-4 inhibitors has not been higher than in the placebo-administered groups. Moreover, in contrast to the reduction in body weight seen after treatment with GLP-1 analogs, DPP-4 inhibitors are body weight neutral. This body weight neutrality distinguishes this class of compound from the increase in body weight, which is associated with treatment with thiazolidinediones and sulfonylureas.
A potential concern during the development of DPP-4 inhibition as a novel therapy has been the potential of DPP-4 to also cleave other bioactive peptides with alanine or proline as the second amino acid from the NH 2 -terminal end (7) . Because these other bioactive peptides may include neuropeptide Y, gastrin-releasing peptide, substance P, and various chemokines, this phenomenon may potentially cause adverse events related to increased blood pressure, neurogenic inflammation, and immunological reactions. However, no such adverse events have been reported in animal studies or in humans using DPP-4 inhibition. It should also be emphasized that it has not been demonstrated that DPP-4 indeed affects the metabolism of these other bioactive peptides in humans; studies referred to previously are mainly in vitro studies in test tubes.
DPP-4 inhibitors and lipid levels
The clinical trials with vildagliptin and sitagliptin have measured fasting levels of lipids, and in general no or very little effects have been found on parameters such as cholesterol and triglycerides. This would suggest that DPP-4 inhibition does not affect lipid metabolism. However, a recent study (46) showed that vildagliptin largely (by 85%) inhibited the triglyceride response to ingestion of a fat-rich meal following a 4-week treatment at 50 mg twice daily in patients with type 2 diabetes. This was seen in association with a 91% reduction in chylomicron apolipoprotein B-48 and chylomicron cholesterol. Hence, vildagliptin improves plasma lipids and lipoprotein particle metabolism after a fat-rich meal, which would be of importance considering the relevance for prandial lipemia as a marker for cardiovascular diseases.
Mechanism of action of DPP-4 inhibition DPP-4 inhibition prevents the inactivation of GLP-1, and this increases GLP-1 levels. The increase in GLP-1 levels is seen throughout 24 h, i.e., both after meal ingestion and in the fasting state (16) . The importance of GLP-1 for the action of DPP-4 inhibitors is evident from animal studies showing that DPP-4 inhibition does not improve glucose homeostasis in mice with genetic deletion of GLP-1 and GIP receptors (47) . GLP-1 in turn stimulates insulin secretion, and it has been documented that acute ␤-cell function is improved also by DPP-4 inhibition. This has been documented for vildagliptin as increased insulin response in relation to the glucose response after meal ingestion (26) and increased estimated insulin secretory rate after modeling insulin and Cpeptide data after meal ingestion (16, 48) . Furthermore, sitagliptin has been shown to increase homeostasis model assessment-B index (a marker for insulin secretion) and to reduce proinsulin-to-insulin ratio (a marker for ␤-cell function) (36) . Animal studies have also shown improved chronic ␤-cell function, such as increased ␤-cell mass, after DPP-4 inhibition (12, 19, 21) . However, no such evidence exists in humans.
Another important mechanism for improved glycemic control by DPP-4 inhibition is inhibition of glucagon secretion, which is an effect by GLP-1 as well. This was initially demonstrated when vildagliptin at 100 mg once or twice daily was given for 4 weeks (26) , and it has also been shown that the entire 24-h glucagon profile is reduced by vildagliptin (16) . Furthermore, a recent study showed that the reduction in glucagon levels in association with increased insulin secretion by administration of 100 mg vildagliptin to subjects with type 2 diabetes was accompanied by inhibition of hepatic glucose production, as determined by clamp technique using tracer glucose (49) . These findings are of great importance considering the inappropriately high glucagon secretion in subjects with type 2 diabetes (50) .
Besides the improvement of islet function, DPP-4 inhibition may also improve insulin sensitivity. This has been found following treatment with vildagliptin using both an indirect measure of insulin sensitivity (48) and the hyperinsulinemic-euglycemic clamp test (51) . This may be a consequence of the reduced glucagon levels seen after
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DPP-4 inhibition in association with improved insulin action due to improved metabolic control.
In contrast to GLP-1, DPP-4 inhibition does not seem to affect gastric emptying, as is evident by the lack of effect of DPP-4 inhibitors on the rate of increase in circulating glucose after meal ingestion. Furthermore, vildagliptin did not affect the rate of gastric emptying of a tracerenriched meal (52) .
SUMMARY -Several DPP-4 inhibitors are in clinical development; one (sitagliptin) has been approved by the FDA, and another (vildagliptin) has been applied for approval. Both of these compounds are efficient with a remarkably low degree of adverse events. Although no head-to-head studies have been reported, the reported studies suggest that these two compounds have similar effects on glycemic control. Therefore, differences between studies relate more likely to the patients in the trials than to the inherent differences between the compounds. The overall experience with DPP-4 inhibition is therefore that they are orally active, safe, and highly tolerable, with a minimal risk for hypoglycemic events. Furthermore, they show sustained, robust, and clinically significant improvement in glycemia in both monotherapy and combination with metformin and thiazolidinediones, and they are body weight neutral. The relevant mechanisms of action of DPP-4 inhibition (mainly improvement of islet function) and the efficacy, tolerability, and safety of treatment suggest that this approach has great potential as a novel treatment. Its place in therapy remains, however, to be explored in more detail. Results presented thus far suggest that DPP-4 inhibition has its strongest potential as a first-line treatment in early stages of type 2 diabetes in combination with metformin and thiazolidinediones. DPP-4 inhibitors are also strong candidates for being established as a first-line treatment as monotherapy, particularly in elderly subjects and in subjects with contraindication or intolerance for metformin or thiazolidinediones. DPP-4 inhibition may also be used in combination with insulin with the great advantage of reducing the likelihood of developing hypoglycemia. Whether DPP-4 inhibition may also be advantageous over existing treatment in longterm therapy of more advanced stages of the disease remains to be established. For further studies, it is important to evaluate the long-term durability and long-term safety as well as action in subsets of patients, such as in the elderly.
